Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.049
-0.061 (-5.50%)
At close: Aug 14, 2026, 4:00 PM EDT
1.049
0.00 (0.04%)
After-hours: Aug 14, 2026, 7:42 PM EDT
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,133,553
Market Cap
4.18M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 9 | 0 | - | 8 | 1 |
| Dec 31, 2024 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2023 | 10 | 4 | 66.67% | 9 | 1 |
| Dec 31, 2022 | 6 | - | - | 6 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| PMGC Holdings | 34 |
| Aptevo Therapeutics | 33 |
| Ernexa Therapeutics | 7 |
| Galmed Pharmaceuticals | 6 |
| Creative Medical Technology Holdings | 4 |
| Mustang Bio | 4 |
| Silo Pharma | 3 |
REVB News
- 8 days ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 - Accesswire
- 8 days ago - Revelation Biosciences Quarterly report: Q2 2026 - Filings
- 8 days ago - Revelation Biosciences Earnings release: Q2 2026 - Filings
- 11 days ago - Revelation Biosciences announces results from market assessment for Gemini - TheFly
- 11 days ago - Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury - Accesswire
- 24 days ago - Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Accesswire
- 5 weeks ago - Revelation Biosciences Announces Adoption of Stockholder Rights Plan - Accesswire
- 2 months ago - Revelation Biosciences Transcript: Transcript - Transcripts